• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Elys Game Technology Joins the U.S. National Council on Problem Gambling in Advance of Launching its Sports Betting Platform in the U.S.

    1/5/21 8:00:00 AM ET
    $ELYS
    $NEO
    Computer Software: Prepackaged Software
    Technology
    Precision Instruments
    Health Care
    Get the next $ELYS alert in real time by email

    NEW YORK--(BUSINESS WIRE)--Elys Game Technology, Corp. (“Elys” or the “Company”) (Nasdaq:ELYS, NEO:ELYS), an interactive gaming and sports betting technology company, announced today that it has joined the National Council on Problem Gambling (NCPG) to further the development and implementation of responsible gambling practices.

    NCPG is a leading U.S. non-governmental organization (NGO) serving as the national advocate for programs and services to assist people and families affected by problem gambling. Through its NCPG membership, Elys will support NCPG‘s wide-ranging problem gambling prevention, treatment, education, and research programs, as well as innovative responsible gambling policies.

    Michele (Mike) Ciavarella, Executive Chairman of Elys Game Technology, Corp., stated, “As we prepare our first U.S. deployment in Washington D.C., we are delighted to become a member of NCPG and support their invaluable work in addressing the critical and widespread need for responsible gambling practices. We are proud to join forces with the esteemed board of directors, members and stakeholders of NCPG to develop and promote national U.S. industry standards in responsible gaming, including the Safer Sports Betting Initiative and Internet Responsible Gambling Standards, which provide critical player services and protections. There is no bigger responsibility for us than ensuring the best and safest possible experience for our gambling operators and their players, while providing assistance for those individuals who show signs of problem gambling behavior. Partnering with NCPG further deepens our commitment to become a leader in responsible gaming and provides us valuable resources as we are preparing for the launch of our sports betting platform in the U.S.”

    Keith Whyte, Executive Director of NCPG, said, “We are excited that Elys has become a member of NCPG, as they bring extensive experience around engaging with millions of players across their sports betting and iGaming platforms. Elys’ broad reach and commitment to responsible gambling will be a tremendous asset to NCPG as we continue raising awareness about problem gambling and the resources available to support those impacted. We look forward to working together with Elys to increase our mutual understanding of player behavior and reduce the risks for gambling problems.”

    Since there is no federal regulation of gambling or federal health insurance for all residents in the U.S., each state makes its own rules to meet its unique structure and goals. B2B and B2C companies like Elys become valuable partners for NCPG, a leading source of objective state-specific information on responsible gambling and problem gambling for the public as well as the gambling industry in the U.S. Companies may create, adapt and update their responsible gambling tools and practices with expert assistance as they work with the varied U.S. state gambling control entities, gambling operators and healthcare providers. In addition, NCPG’s National Problem Gambling Helpline Network is the only source of problem gambling help in many areas of the country. Members like Elys make this possible.

    About Elys Game Technology, Corp.

    Elys Game Technology, Corp., is a B2B global gaming technology company operating in multiple countries worldwide, with B2C online and land-based gaming operations in Italy. In Italy, Elys offers its clients a full suite of leisure gaming products and services, such as sports betting, e-sports, virtual sports, online casino, poker, bingo, interactive games and slots.

    The Company’s innovative wagering solution services online operators, casinos, retail betting establishments and franchise distribution networks. The Company has completed the product regulatory requirements to commence B2B operations in the United States. Additional information is available on our corporate website at www.elysgame.com.

    Investors may also find us on Twitter @ELYS_gaming.

    About the National Council on Problem Gambling

    NCPG is the only U.S. national advocate for people and families affected by problem gambling and is supported by members and donors; there is no federal funding for problem gambling services. NCPG is neutral on legalized gambling and works with all stakeholders to promote responsible gambling. If you or someone you know has a gambling problem, from anywhere in the U.S. you can call or text the National Problem Gambling Helpline Network at 1-800-522-4700 or visit www.ncpgambling.org/chat for confidential help 24/7/365. The call is free and confidential, and translation services are available in over 150 languages.

    Forward-Looking Statements

    This press release contains certain forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified by the use of the words “could,” “believe,” “anticipate,” “intend,” “estimate,” “expect,” “may,” “continue,” “predict,” “potential,” “project” and similar expressions that are intended to identify forward-looking statements and include statements regarding the Company’s first U.S. deployment in Washington D.C.. These forward-looking statements are based on management’s expectations and assumptions as of the date of this press release and are subject to a number of risks and uncertainties, many of which are difficult to predict that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the Company’s ability to deploy as planned in Washington, D.C., the duration and scope of the COVID-19 outbreak worldwide, including the impact to the state and local economies, and the risk factors described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019 and its subsequent filings with the U.S. Securities and Exchange Commission, including subsequent periodic reports on Form 10-Q and current reports on Form 8-K. The information in this release is provided only as of the date of this release, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events, except as required by law.

    Get the next $ELYS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ELYS
    $NEO

    CompanyDatePrice TargetRatingAnalyst
    NeoGenomics Inc.
    $NEO
    7/30/2025Buy → Neutral
    BTIG Research
    NeoGenomics Inc.
    $NEO
    7/29/2025Outperform → Mkt Perform
    William Blair
    NeoGenomics Inc.
    $NEO
    5/15/2025Neutral
    Guggenheim
    NeoGenomics Inc.
    $NEO
    4/30/2025$9.00Outperform → Market Perform
    Leerink Partners
    NeoGenomics Inc.
    $NEO
    1/13/2025Buy → Hold
    The Benchmark Company
    NeoGenomics Inc.
    $NEO
    12/10/2024$22.00Buy
    Jefferies
    NeoGenomics Inc.
    $NEO
    5/1/2024$26.00Buy
    Craig Hallum
    NeoGenomics Inc.
    $NEO
    12/29/2023$25.00 → $21.00Buy
    BTIG Research
    More analyst ratings

    $ELYS
    $NEO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    NeoGenomics downgraded by BTIG Research

    BTIG Research downgraded NeoGenomics from Buy to Neutral

    7/30/25 7:31:39 AM ET
    $NEO
    Precision Instruments
    Health Care

    NeoGenomics downgraded by William Blair

    William Blair downgraded NeoGenomics from Outperform to Mkt Perform

    7/29/25 12:56:34 PM ET
    $NEO
    Precision Instruments
    Health Care

    Guggenheim initiated coverage on NeoGenomics

    Guggenheim initiated coverage of NeoGenomics with a rating of Neutral

    5/15/25 8:12:40 AM ET
    $NEO
    Precision Instruments
    Health Care

    $ELYS
    $NEO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NeoGenomics Launches PanTracer LBx, Expanding Access to Comprehensive Genomic Profiling with Liquid Biopsy

    New ctDNA-based test offers a flexible, guideline-driven solution for patients with advanced solid tumors when tissue is limited or unavailable NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the launch of NEO PanTracer™ LBx, a blood-based comprehensive genomic profiling (CGP) test, expanding the company's PanTracer portfolio. PanTracer LBx is a noninvasive test designed to support therapy selection, trial matching, and longitudinal monitoring, empowering data-driven decisions even when tumor tissue is limited or unavailable. "The launch of our liquid biopsy test positions us at the forefront of the prec

    7/30/25 7:05:00 AM ET
    $NEO
    Precision Instruments
    Health Care

    NeoGenomics Reports Second Quarter 2025 Results

    Second Quarter Revenue Increased 10% to $181 million; Clinical Revenue Grew 16%, 13% excluding Pathline; Updates Full Year 2025 Guidance NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced its second-quarter results for the period ended June 30, 2025. Second Quarter 2025 Highlights As Compared To Second Quarter 2024   Consolidated revenue increased 10% to record $181 million   Net loss increased 142% to $45 million including $20 million of impairment charges   Adjusted EBITDA remained relatively flat at positive $11 million  

    7/29/25 7:05:00 AM ET
    $NEO
    Precision Instruments
    Health Care

    NeoGenomics to Report Second Quarter 2025 Financial Results on July 29, 2025

    NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it will report its second quarter 2025 financial results prior to the open of the U.S. financial markets on Tuesday, July 29, 2025. Company management will host a webcast and conference call at 8:30 a.m. ET to discuss financial results and recent highlights. The live webcast may be accessed by visiting the Investor Relations section of our website at ir.neogenomics.com or by clicking here. The webcast will be archived and available for replay shortly after the conclusion of the call. To access the live call via telephone, dial (888) 506-0062 (domestic)

    7/1/25 7:05:00 AM ET
    $NEO
    Precision Instruments
    Health Care

    $ELYS
    $NEO
    SEC Filings

    View All

    NeoGenomics Inc. filed SEC Form 8-K: Leadership Update

    8-K - NEOGENOMICS INC (0001077183) (Filer)

    8/8/25 4:03:26 PM ET
    $NEO
    Precision Instruments
    Health Care

    SEC Form 10-Q filed by NeoGenomics Inc.

    10-Q - NEOGENOMICS INC (0001077183) (Filer)

    7/29/25 7:22:17 AM ET
    $NEO
    Precision Instruments
    Health Care

    NeoGenomics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - NEOGENOMICS INC (0001077183) (Filer)

    7/29/25 7:08:17 AM ET
    $NEO
    Precision Instruments
    Health Care

    $ELYS
    $NEO
    Financials

    Live finance-specific insights

    View All

    NeoGenomics Reports Second Quarter 2025 Results

    Second Quarter Revenue Increased 10% to $181 million; Clinical Revenue Grew 16%, 13% excluding Pathline; Updates Full Year 2025 Guidance NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced its second-quarter results for the period ended June 30, 2025. Second Quarter 2025 Highlights As Compared To Second Quarter 2024   Consolidated revenue increased 10% to record $181 million   Net loss increased 142% to $45 million including $20 million of impairment charges   Adjusted EBITDA remained relatively flat at positive $11 million  

    7/29/25 7:05:00 AM ET
    $NEO
    Precision Instruments
    Health Care

    NeoGenomics to Report Second Quarter 2025 Financial Results on July 29, 2025

    NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it will report its second quarter 2025 financial results prior to the open of the U.S. financial markets on Tuesday, July 29, 2025. Company management will host a webcast and conference call at 8:30 a.m. ET to discuss financial results and recent highlights. The live webcast may be accessed by visiting the Investor Relations section of our website at ir.neogenomics.com or by clicking here. The webcast will be archived and available for replay shortly after the conclusion of the call. To access the live call via telephone, dial (888) 506-0062 (domestic)

    7/1/25 7:05:00 AM ET
    $NEO
    Precision Instruments
    Health Care

    NeoGenomics Reports First Quarter 2025 Results

    Consolidated Revenue Increased 8% to $168 million NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced its first-quarter results for the period ended March 31, 2025. First Quarter 2025 Highlights As Compared To First Quarter 2024 Consolidated revenue increased 8% to $168 million Net loss decreased 4% to $26 million Adjusted EBITDA increased 102% to positive $7 million "Our business is off to a solid start in 2025 with our team delivering a record number of results to patients in the first quarter and improving our adjusted EBITDA by over 100% from prior year," said Ton

    4/29/25 7:30:00 AM ET
    $NEO
    Precision Instruments
    Health Care

    $ELYS
    $NEO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Sherman Jeffrey Scott bought $112,322 worth of shares (20,000 units at $5.62), increasing direct ownership by 12% to 188,332 units (SEC Form 4)

    4 - NEOGENOMICS INC (0001077183) (Issuer)

    8/6/25 4:07:57 PM ET
    $NEO
    Precision Instruments
    Health Care

    Chief Executive Officer Zook Anthony P. bought $99,954 worth of shares (17,900 units at $5.58), increasing direct ownership by 89% to 38,066 units (SEC Form 4)

    4 - NEOGENOMICS INC (0001077183) (Issuer)

    8/6/25 4:07:25 PM ET
    $NEO
    Precision Instruments
    Health Care

    Director Kelly Michael Aaron bought $38,000 worth of shares (5,000 units at $7.60) (SEC Form 4)

    4 - NEOGENOMICS INC (0001077183) (Issuer)

    5/28/25 4:07:40 PM ET
    $NEO
    Precision Instruments
    Health Care

    $ELYS
    $NEO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Sherman Jeffrey Scott bought $112,322 worth of shares (20,000 units at $5.62), increasing direct ownership by 12% to 188,332 units (SEC Form 4)

    4 - NEOGENOMICS INC (0001077183) (Issuer)

    8/6/25 4:07:57 PM ET
    $NEO
    Precision Instruments
    Health Care

    Chief Executive Officer Zook Anthony P. bought $99,954 worth of shares (17,900 units at $5.58), increasing direct ownership by 89% to 38,066 units (SEC Form 4)

    4 - NEOGENOMICS INC (0001077183) (Issuer)

    8/6/25 4:07:25 PM ET
    $NEO
    Precision Instruments
    Health Care

    EVP, GC & Business Development Olivo Alicia C covered exercise/tax liability with 14 shares, decreasing direct ownership by 0.03% to 49,606 units (SEC Form 4)

    4 - NEOGENOMICS INC (0001077183) (Issuer)

    8/5/25 4:38:59 PM ET
    $NEO
    Precision Instruments
    Health Care

    $ELYS
    $NEO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by NeoGenomics Inc.

    SC 13G/A - NEOGENOMICS INC (0001077183) (Subject)

    11/14/24 1:28:29 PM ET
    $NEO
    Precision Instruments
    Health Care

    SEC Form SC 13G filed by NeoGenomics Inc.

    SC 13G - NEOGENOMICS INC (0001077183) (Subject)

    2/14/24 10:04:34 AM ET
    $NEO
    Precision Instruments
    Health Care

    SEC Form SC 13G/A filed by NeoGenomics Inc. (Amendment)

    SC 13G/A - NEOGENOMICS INC (0001077183) (Subject)

    2/13/24 5:09:41 PM ET
    $NEO
    Precision Instruments
    Health Care

    $ELYS
    $NEO
    Leadership Updates

    Live Leadership Updates

    View All

    NeoGenomics Appoints Dr. Marjorie Green to Board of Directors

    NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the appointment of Marjorie Green to its Board of Directors, effective June 19, 2025. Dr. Green is currently Senior Vice President and Head of Oncology, Global Clinical Development at Merck. Dr. Green, a seasoned executive with extensive experience in the life sciences industry, brings a strong track record of leadership in oncology, corporate strategy, and business development. As Head of Oncology, Global Clinical Development at Merck, a premier biopharmaceutical company, she oversees the company's research for its single biggest area of commercial revenue a

    6/24/25 7:05:00 AM ET
    $NEO
    Precision Instruments
    Health Care

    NeoGenomics Appoints Warren Stone as President & Chief Operating Officer

    Stone to drive lab operations, data solutions division and enterprise operations functions in addition to existing commercial responsibilities Leadership team aligned to support long term growth, profitability, and operational execution NeoGenomics, Inc. ("NeoGenomics" or the "Company") (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it has promoted Warren Stone, the Company's current Chief Commercial Officer (CCO), to President & Chief Operating Officer, effective April 1, 2025. Mr. Stone has over 25 years of general management and cross-functional commercial experience. In his expanded role, he will be responsible f

    3/18/25 7:05:00 AM ET
    $NEO
    Precision Instruments
    Health Care

    PacBio Announces Appointment of Chris Smith to Board of Directors

    MENLO PARK, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the appointment of Chris Smith to its Board of Directors, effective today. Mr. Smith is currently the Chief Executive Officer of NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company. Mr. Smith, a seasoned executive with extensive experience in the life sciences and healthcare industries, brings a strong track record of leadership in genomics, diagnostics, and corporate strategy. As CEO of NeoGenomics, a leading provider of oncology testing services, he has overseen the company's continued growth and in

    1/30/25 9:05:00 AM ET
    $NEO
    $PACB
    Precision Instruments
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials